While still in its infancy, the bioprinting industry continues to capture the fascination and passion of both bioengineers and those of us who are just amazed by its promises. Which are great but also difficult to assess and keep track of. At 3dpbm we work to look at the state of the commercial bioprinting industry at least every two years and we do so through our eBooks: welcome to our Bioprinting AM Focus 2022 eBook
This year, for our appointment with medical AM applications, we dedicated the entire issue to bioprinting companies, advancements and the latest research. We present new insights and features that showcase how bioprinting is not only evolving from a purely academic segment into a real industry but also how research is getting closer to delivering the first end-use bioprinted applications.
In our analysis chapter, we first traced the state of the art of the companies that are emerging and defining the global market, the latest bioprinting hardware technologies, the growing number of available materials (bioinks, cells and organoids), and the possible applications in and beyond academic research, including a look at the very real possibilities for cosmetics testing and cellular agriculture.
Perhaps the most down-to-Earth and fascinating story that we are exclusively covering in this issue is the innovative tissue engineering project for treating microtia from T&R Biofab reveals, which was inspired by the groundbreaking Vacanti mouse experiment (of which this year is the 25th anniversary).
A lot happened during our AM Focus Bioprinting month that saw research projects which originated nearly a decade ago evolve into commercial opportunities: on the one hand, the pioneering research by Harvard Wyss Professor Jennifer Lewis on capillarization of bioprinted renal tissue was patented by Trestle Biotherapeutics (we have more exclusive information on this coming in the next few weeks), and on the other the equally pioneering group at Utrecht University with Professor Jos Malda and Ricardo Levato showed for the first time the volumetric 3D printing of functional liver tissue units (read the full story of their group and their spinoff startup Readily3D in the eBook).
Because, just like in every AM market segment, materials are the key (even more so in bioprinting), we decided to focus our map in this Bioprinting AM Focus issue on some of the most interesting companies active in bioink segment, from the largest companies like Advanced Biomatrix (part of the bioconvergence market leading BICO group) and Rousselot to highly innovative companies like Humabiologics and Jellagen.
In this issue, we also have a great contribution from bioprinting segment expert and serial startupper Stephen Gray, who analyzes the state of the art of bioprinting technology starting with the provocatory claim that extrusion 3D printing may soon be replaced by other commercial bioprinting technologies (and the article also shows that it’s alive and well now). Yet, companies like Fluicell are bringing advanced technologies with single-cell to more users than ever with new systems such as the just-launched Biopixlar AER.
You can find some of our recent eBook editions below:
- Automotive AM Focus 2022 eBook
- Ceramic AM Focus 2021 eBook
- Metal AM Focus 2021 eBook
- AM Services AM Focus 2021 eBook
- Post Processing AM Focus 2021 eBook
Interested in being featured in a future AM Focus 2022 eBook? Get in touch to discuss collaboration opportunities.